Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track

Tenaya Therapeutics, Inc.

2023-Q2 EPS reported -$1.44

Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.
Cash, equivalents and marketable securities $180.9M; expected to fund operations into H2 2023.
IND submissions for TN-201 (MYBPC3) and TN-301 (HDAC6) remain on track for H2 2022.
Manufacturing facility in Union City launched, state-licensed for cGMP drug product at 1000L scale.
Preclinical data presented on TN-401 (PKP2 gene therapy) and novel AAV capsids improving cardiac tropism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.